CN Patent

CN115066236A — 糖尿病性黄斑水肿和视敏度受损的治疗

Assigned to Kalvista Pharmaceuticals Ltd · Expires 2022-09-16 · 4y expired

What this patent protects

本发明涉及糖尿病性黄斑水肿(DME)和视敏度受损的治疗，其包括玻璃体内施用式(A)的化合物(或其药用盐和/或溶剂化物)：

USPTO Abstract

本发明涉及糖尿病性黄斑水肿(DME)和视敏度受损的治疗，其包括玻璃体内施用式(A)的化合物(或其药用盐和/或溶剂化物)：

Drugs covered by this patent

Lignospan Forte (Lidocaine Hydrochloride) · Fresenius Kabi

Patent Metadata

Patent number: CN115066236A
Jurisdiction: CN
Classification: —
Expires: 2022-09-16
Drug substance claim: No
Drug product claim: No
Assignee: Kalvista Pharmaceuticals Ltd
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.